Justine Ra is a healthcare reporter for Clinical Trials Arena and Pharmaceutical Technology, focusing coverage on neurology and neurodegenerative diseases. Justine holds a degree in English from The University of Michigan, Ann Arbor.
The company aims to drive a small molecule resurgence with its lead Alzheimer’s symptom relief agent AD-101.
The deal will see ImmunityBio receiving an upfront $210m combination of equity and royalty financing from Oberland.
Wainua will enter the US market in January 2024 after positive Phase III data landed it an FDA approval for ATTRv-PN.
By cutting programs and 46% of staff, Aclaris becomes the latest company to implement restructuring measures in a bid to free capital.
The latest $389m pledge follows an initial investment of $300m in 2017 that was raised to fund early-stage life-science startups.
Give your business an edge with our leading industry insights.
Acadia received two patent rulings that strengthen Nuplazid’s patent position and protect the drug into 2038.
The license of Maze’s GYS1 program, including MZE001, was the subject of FTC opposition, leading to Sanofi terminating the agreement
VIPER-101 has received FDA clearance to begin clinical studies in the midst of a broader investigation on CAR-T cell therapies.
IGM will lay off 22% of its staff and suspend four clinical activities to advance autoimmune diseases and colorectal cancer programmes.
Everest’s clinical trial in China will contribute to Kezar’s global PALIZADE study of zetomipzomib for lupus nephritis